|Title:||How to Improve Therapeutic Ratio in Radiotherapy of HCC||Authors:||Tsai, Chiao-Ling
Cheng, Jason Chia-Hsien
|Keywords:||Biomarkers;Hepatocellular carcinoma;Molecular targeted agents;Radiation therapy||Issue Date:||2016||Start page/Pages:||210-220||Source:||Liver Cancer||Abstract:||
Background: During the past two decades, external-beam radiation technology has substantially changed from traditional two-dimensional to conformal three-dimensional to intensity-modulated planning and stereotactic body radiotherapy (SBRT). Summary: Modern techniques of radiotherapy (RT) are highly focused and capable of delivering an ablative dose to targeted hepatocellular carcinoma (HCC) tumors. SBRT is an option for selected patients with limited tumor volume and non-eligibility for other invasive treatments. Moreover, RT combined with a radiation sensitizer (RS) to increase the therapeutic ratio has shown promising results in select studies, prompting further investigation of this combination. With the undetermined role of RT in treatment guidelines and variation in patterns of treatment failure after RT in patient with HCC, useful biomarkers to guide RT decision-making and selection of patients are needed and emerging. Key Message: The objective of this review is to summarize the current RS with SBRT schemes and biomarkers for patient selection used to maximize the effect of RT on HCC. Copyright (C) 2016 S. Karger AG, Basel
|Appears in Collections:||腫瘤醫學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.